source
- Moderna sticks to 10% revenue growth goal despite Phase 3 norovirus vaccine missModerna said it will continue to aim for up to 10% revenue growth this year, even though its experimental norovirus vaccine did not achieve statistical significance in a Phase 3 interim analysis.…
- Madrigal spends $255 million on multiple MASH drug deals to complement RezdiffraMadrigal Pharmaceuticals is expanding its MASH pipeline by acquiring several assets that could be used alongside its lead candidate, Rezdiffra. In early 2026 the company paid $50 million to Pfizer…